Life-threatening hypophosphataemia secondary to zoledronic acid implementation in a middle-age patient who presented with advanced osteolysis in the course of multiple myeloma

Endokrynol Pol. 2020;71(1):100-101. doi: 10.5603/EP.a2019.0048. Epub 2019 Nov 4.

Authors

Mikołaj Radziszewski¹, Anna Karpiłowska², Joanna Podgórska³, Anna Ziółkowska², Michał Popow²

Affiliations

¹ Department of Internal Medicine and Endocrinology, University Clinical Centre, Medical University of Warsaw, Warsaw, Poland. m.a.radziszewski92@gmail.com.
² Department of Internal Medicine and Endocrinology, University Clinical Centre, Medical University of Warsaw, Warsaw, Poland.
³ 2nd Department of Clinical Radiology, University Clinical Centre, Medical University of Warsaw, Warsaw, Poland.

PMID: 31681977
DOI: 10.5603/EP.a2019.0048

Abstract

Not required for Clinical Vignette.

Keywords: hypophosphatemia; multiple myeloma; osteolysis; zoledronic acid.

Publication types

Case Reports

MeSH terms

Bone Density Conservation Agents / adverse effects
Humans
Hypophosphatemia / chemically induced
Hypophosphatemia / diagnosis*
Male
Middle Aged
Multiple Myeloma / complications*
Multiple Myeloma / diagnosis
Osteolysis / complications*
Osteolysis / diagnosis
Zoledronic Acid / adverse effects

Substances

Bone Density Conservation Agents
Zoledronic Acid